Pharma Major Lupin announced the launch of its Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
 
Lupin's Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP’s Seroquel XR Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

It is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.
 
Seroquel XR Tablets had US sales of USD 1.1 billion (IMS MAT June 2017). 

Shares of the company gained Rs 10.55, or 1.12%, to settle at Rs 954.80. The total volume of shares traded was 79,187 at the BSE (Wednesday).